CY1118435T1 - Παραγωγο μορφολινο νουκλεϊνικου οξεος - Google Patents

Παραγωγο μορφολινο νουκλεϊνικου οξεος

Info

Publication number
CY1118435T1
CY1118435T1 CY20171100027T CY171100027T CY1118435T1 CY 1118435 T1 CY1118435 T1 CY 1118435T1 CY 20171100027 T CY20171100027 T CY 20171100027T CY 171100027 T CY171100027 T CY 171100027T CY 1118435 T1 CY1118435 T1 CY 1118435T1
Authority
CY
Cyprus
Prior art keywords
morpholine
nuclear acid
acid producer
nucleic acid
provides
Prior art date
Application number
CY20171100027T
Other languages
English (en)
Inventor
Toshihiro Ueda
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of CY1118435T1 publication Critical patent/CY1118435T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένα χρήσιμο παράγωγο μορφολινο νουκλεϊνικού οξέος για σύνθεση ενός ολιγομερούς μορφολινο νουκλεϊνικού οξέος. Η παρούσα εφεύρεση παρέχει μια ένωση που αντιπροσωπεύεται από τον παρακάτω γενικό τύπο (1) ή ένα άλας.
CY20171100027T 2010-09-30 2017-01-10 Παραγωγο μορφολινο νουκλεϊνικου οξεος CY1118435T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010220865 2010-09-30
PCT/JP2011/072407 WO2012043730A1 (ja) 2010-09-30 2011-09-29 モルホリノ核酸誘導体

Publications (1)

Publication Number Publication Date
CY1118435T1 true CY1118435T1 (el) 2017-06-28

Family

ID=45893168

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100027T CY1118435T1 (el) 2010-09-30 2017-01-10 Παραγωγο μορφολινο νουκλεϊνικου οξεος

Country Status (18)

Country Link
US (1) US8969551B2 (el)
EP (1) EP2623507B1 (el)
JP (1) JP5831455B2 (el)
KR (1) KR101764462B1 (el)
CN (1) CN103154009B (el)
CA (1) CA2813183C (el)
CY (1) CY1118435T1 (el)
DK (1) DK2623507T3 (el)
ES (1) ES2607603T3 (el)
HR (1) HRP20170028T1 (el)
HU (1) HUE030292T2 (el)
LT (1) LT2623507T (el)
PL (1) PL2623507T3 (el)
PT (1) PT2623507T (el)
RS (1) RS55610B1 (el)
SI (1) SI2623507T1 (el)
SM (1) SMT201700038B (el)
WO (1) WO2012043730A1 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
CN102203253B (zh) 2008-10-24 2016-04-06 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
CN105838714B (zh) 2009-11-12 2020-07-17 西澳大利亚大学 反义分子和治疗疾病的方法
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MX354940B (es) 2011-11-18 2018-03-27 Sarepta Therapeutics Inc Oligonucleotidos funcionalmente modificados y subunidades de los mismos.
KR102079284B1 (ko) 2012-03-20 2020-02-19 사렙타 쎄러퓨틱스, 인코퍼레이티드 올리고뉴클레오티드 유사체의 보론산 접합체
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
BR122020016865B1 (pt) 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
CN105228999B (zh) 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
US20150197534A1 (en) 2013-09-05 2015-07-16 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
WO2015175977A2 (en) 2014-05-16 2015-11-19 Geller Bruce L Antisense antibacterial compounds and methods
JP6687542B2 (ja) 2014-05-19 2020-04-22 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
WO2016060135A1 (ja) * 2014-10-14 2016-04-21 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
EP3240794A4 (en) 2014-12-31 2018-10-31 Oregon State University Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP4306538A3 (en) 2015-05-19 2024-05-01 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6873052B2 (ja) 2015-06-01 2021-05-19 サレプタ セラピューティクス，インコーポレイテッド Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
IL284611B2 (en) 2015-08-05 2023-11-01 Eisai R&D Man Co Ltd Chiral reagents for the preparation of homogeneous oligomers
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2017106304A1 (en) * 2015-12-15 2017-06-22 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP7393121B2 (ja) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー アンチセンス抗菌化合物および方法
WO2017112885A1 (en) 2015-12-23 2017-06-29 David Greenberg Antisense antibacterial compounds and methods
US11060089B2 (en) 2016-04-18 2021-07-13 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
AU2017258642B2 (en) 2016-04-29 2023-08-31 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human LMNA
MX2018014123A (es) 2016-05-24 2019-04-29 Sarepta Therapeutics Inc Procesos para preparar oligomeros de morfolino fosforodiamidato.
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
KR102506298B1 (ko) 2016-05-24 2023-03-06 사렙타 쎄러퓨틱스 인코퍼레이티드 올리고머의 제조 방법
US20190275072A1 (en) 2016-05-24 2019-09-12 Sarepta Therapeutics, Inc. Pharmaceutical compositions comprising eteplirsen
SG11201809499UA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
JP7022079B2 (ja) 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
EP3515445A4 (en) * 2016-09-20 2020-05-27 The Regents of The University of Colorado, A Body Corporate SYNTHESIS OF SKELETON AND CHIMERIC MODIFIED MORPHOLINO OLIGONUCLEOTIDES USING PHOSPHORAMIDITY CHEMISTRY
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
JP7218361B2 (ja) * 2017-09-25 2023-02-06 サレプタ セラピューティクス， インコーポレイテッド 高速流動合成を介してホスホロジアミデートモルホリノオリゴマーを調製するための方法
EP3697910A4 (en) 2017-10-18 2021-07-14 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
SG11202011094PA (en) 2018-05-10 2020-12-30 Nippon Shinyaku Co Ltd Method for preparing oligonucleic acid compound
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
JPWO2021095875A1 (el) 2019-11-13 2021-05-20
CA3161586A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
KR20230035623A (ko) * 2020-07-10 2023-03-14 창저우 신더올 파마슈티컬스 컴퍼니 리미티드 올리고뉴클레오티드의 제조 방법
KR20240004559A (ko) * 2021-04-28 2024-01-11 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
MX2023012559A (es) 2021-04-30 2023-12-15 Sarepta Therapeutics Inc Métodos de tratamiento para la distrofia muscular.
EP4419680A1 (en) 2021-10-22 2024-08-28 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
CN118488959A (zh) 2021-12-27 2024-08-13 日本新药株式会社 低聚核酸化合物的制造方法
WO2023167908A1 (en) * 2022-03-01 2023-09-07 Eisai R&D Management Co., Ltd. Bis-protected, activated guanine monomers
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009033A1 (en) 1989-12-20 1991-06-27 Anti-Gene Development Group Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2005255530A (ja) 2004-03-09 2005-09-22 Japan Science & Technology Agency ２−チオウリジン誘導体
LT2735568T (lt) * 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009064471A1 (en) * 2007-11-15 2009-05-22 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers

Also Published As

Publication number Publication date
JPWO2012043730A1 (ja) 2014-02-24
PL2623507T3 (pl) 2017-03-31
EP2623507A4 (en) 2014-03-19
CN103154009B (zh) 2015-06-10
US8969551B2 (en) 2015-03-03
ES2607603T3 (es) 2017-04-03
CA2813183A1 (en) 2012-04-05
US20130197220A1 (en) 2013-08-01
RS55610B1 (sr) 2017-06-30
KR20130143045A (ko) 2013-12-30
WO2012043730A1 (ja) 2012-04-05
DK2623507T3 (da) 2017-01-02
SI2623507T1 (sl) 2017-04-26
EP2623507A1 (en) 2013-08-07
HUE030292T2 (en) 2017-04-28
SMT201700038B (it) 2017-03-08
EP2623507B1 (en) 2016-11-02
HRP20170028T1 (hr) 2017-03-24
KR101764462B1 (ko) 2017-08-02
JP5831455B2 (ja) 2015-12-09
CA2813183C (en) 2017-09-19
PT2623507T (pt) 2016-12-23
LT2623507T (lt) 2017-01-25
CN103154009A (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
CY1118435T1 (el) Παραγωγο μορφολινο νουκλεϊνικου οξεος
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
UA113643C2 (xx) N-цикліламіди як нематоциди
BR112015000160A2 (pt) fabricação de ácido 2-(5-bromo-4-(4-ciclopropil hidronaftalen-1-il)-4h-1,2,4-triazol-3-il-tio) acético
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20110474A (es) Derivados de benzofurano
EA201290800A1 (ru) Гетероциклическое соединение
RS54730B1 (sr) Inhibitori beta sekretaze
EA201101099A1 (ru) Гербициды, полученные из циклопентадиона
EA200900945A1 (ru) Новый способ синтеза агомелатина
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
CY1116974T1 (el) Παραγωγα 5-υδροξυπυριμιδινο-4-καρβοξαμιδιου
EA200900946A1 (ru) Новый способ синтеза агомелатина
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
AU2012310674B2 (en) Radioactive fluorine labeled compound
CY1117912T1 (el) Ενωσεις πυραζολιου ως αναστολεiς του συμμεταφορεα νατριου-γλυκοζης 1 (sglt1)
IN2014CN04960A (el)
MX2017017022A (es) Metodo para la sintesis de derivados de rapamicina.
CY1119040T1 (el) Μεθοδος για την παρασκευη 1-([1,3]διοξολαν-4-υλομεθυλο)-1η-πυραζολ-3-υλαμινης
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης